Table 1. Patients’ characteristics.
| Characteristics | N (%) | |
|---|---|---|
| Age (years) (n = 83) | ||
| Median | 65 | |
| Range | 40–80 | |
| Performance status | ||
| 0 | 75 (90) | |
| 1 | 6 (7) | |
| 2 | 2 (2) | |
| Sex | ||
| Male | 79 (95) | |
| Female | 4 (5) | |
| Follow up (month) | ||
| Median | 32 | |
| Range | 2–127 | |
| Progression-free survival(month) | ||
| Median | 24 | |
| Range | 1–127 | |
| Overall survival (month) | ||
| Median | 32 | |
| Range | 2–127 | |
| Current status | ||
| Dead | 48 (58) | |
| Alive | 35 (42) | |
| Smoking status | ||
| Never | 5 (6) | |
| Mild | 33 (40) | |
| Heavy | 45 (54) | |
| Alcohol status | ||
| Never | 5 (6) | |
| Moderate | 38 (46) | |
| Heavy | 40 (48) | |
| Differentiation | ||
| Well differentiated | 30 (36) | |
| Moderately differentiated | 42 (51) | |
| Poorly differentiated | 11 (13) | |
| Subsite | ||
| Pyriform sinus | 70 (84) | |
| Post cricoid | 6 (7) | |
| Posterior wall | 7 (8) | |
| T stage | ||
| T1 | 0 | |
| T2 | 15 (18) | |
| T3 | 38 (46) | |
| T4 | 30 (36) | |
| N Stage | ||
| N0 | 10 (12) | |
| N1 | 13 (16) | |
| N2 | 49 (59) | |
| N3 | 11 (13) | |
| Stage | ||
| III | 16 (19) | |
| IVA | 55 (66) | |
| IVB | 12 (15) | |
| NAC categories | ||
| PF | 45 (54) | |
| TPF | 38 (46) | |
| Response to NAC | ||
| Complete response | 0 | |
| Partial response | 39 (47) | |
| Stable disease | 34 (41) | |
| Progressive disease | 10 (12) | |
| Definitive treatment | ||
| Surgery | 48 (58) | |
| CCRT | 29 (35) | |
| Palliation | 6 (7) | |
| Postoperative treatment | ||
| None | 20 (24) | |
| RT | 20 (24) | |
| CCRT | 8 (10) | |
| HLA class I expression | ||
| < 25% | 35 (42) | |
| 25–74 | 34 (41) | |
| ≥ 75% | 14 (17) | |
| PD-L1 TPS | ||
| < 1% | 57 (68) | |
| 1%–49% | 13 (16) | |
| ≥ 50% | 13 (16) |
NAC, neoadjuvant chemotherapy; PF, cisplatin and 5-fluorouracil; TPF, docetaxel, cisplatin, and 5-fluorouracil; TPS, tumor proportion score; CCRT, concurrent chemoradiotherapy.